This is an interview with Kyle Cetrulo, Founder and CEO of AuxoCell Laboratories, a company specializing in solid tissue processing using its AC:Px System. In addition to heading Auxocell and being a thought-leader on perinatal stem cells, Kyle is an organizer for the upcoming 2nd Annual Perinatal Stem Cell Society Conference that will take place each March in Aspen, CO.
[Read more…]
Hematopoietic Stem Cells (HSCs)
Could NiCord® by Gamida Cell Introduce a Paradigm Shift to HSCT?
Gamida Cell is an Israeli company specializing in cellular and immune therapies for the treatment of cancer and orphan genetic diseases. The company is developing a diverse clinical pipeline based on its proprietary NAM technology platform. It lead program, NiCord®, is now in Phase 3 development for allogeneic bone marrow transplantation.
NiCord® was granted Breakthrough Therapy Designation by the FDA, as well orphan drug designation by the European Medicines Agency (EMA). [Read more…]
Cord Blood Industry Trends – Clinical Trials, Publications, Patents, Grants, & More
With the global cord blood banking industry maturing and consolidating over the past five years, it is more important than ever to be well-educated about cord blood industry trends. There are now fewer market players, because numerous small cord blood banks have either been acquired or gone out of business.
However, this era of maturation and consolidation has had as many benefits to surviving cord blood banks as drawbacks. On average, the remaining market participants are now larger, stronger, better capitalized, and storing larger quantities of cord blood and tissue units than when the market was more fragmented.
Cord Blood Processing Method PrepaCyte-CB Leads in Engraftment Time
The cord blood processing method PrepaCyte-CB has been shown to engraft more quickly during the vital stage of post-transplant recovery than any other processing method. At the 15th Annual International Cord Blood Symposium in San Diego, California, in June 2017, the St. Louis Cord Blood Bank presented the median time it took patients infused with cord blood using either its Hetastarch or PrepaCyte-CB processing method to reach an absolute neutrophil count (ANC) of 500.
PrepaCyte-CB was found to engraft a full four days more quickly than the Hetastarch processing method (16 days versus 20 days) and has shown to be just as safe to the patient.1 Combining this data with those of other public data sources, PrepaCyte-CB was found to engraft more quickly than any other processing method. [Read more…]
Growth Rates & Trends within the Cord Blood Industry – Interview with Kenneth Harris
I had the honor of interviewing Kenneth Harris, Chief Advisor for CuraSense Advisors about cord blood industry growth rates and trends. There are many misleading metrics being released about the cord blood banking industry, so it was an honor to speak with another person who is extremely knowledgeable about the cord blood banking field. In this interview, we explore growth rates for the global cord blood industry, key trends affecting the industry, differences in geographic opportunities and more. Enjoy. [Read more…]
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 31
- Next Page »